Terms: = Lung cancer AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C
41 results:
1. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus.
Leonhardt CS; Stamm T; Hank T; Prager G; Strobel O
ESMO Open; 2023 Dec; 8(6):102067. PubMed ID: 37988953
[TBL] [Abstract] [Full Text] [Related]
2. Local control strategies for management of NSCLC with oligoprogressive disease.
Mavrikios A; Remon J; Quevrin C; Mercier O; Tselikas L; Botticella A; Nicolas E; Deutsch E; Besse B; Planchard D; Barlesi F; Le Péchoux C; Levy A
Cancer Treat Rev; 2023 Nov; 120():102621. PubMed ID: 37690180
[TBL] [Abstract] [Full Text] [Related]
3. Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic lung Adenocarcinoma.
Yang G; Kim KH; Lee CG; Hong MH; Kim HR; Cho Y; Yoon HI
Cancer Res Treat; 2024 Jan; 56(1):115-124. PubMed ID: 37641819
[TBL] [Abstract] [Full Text] [Related]
4. Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi-institutional consortium.
Id Said B; Mutsaers A; Chen H; Husain ZA; Biswas T; Dagan R; Erler D; Foote M; Louie AV; Redmond K; Ricardi U; Sahgal A; Poon I
Head Neck; 2023 Oct; 45(10):2627-2637. PubMed ID: 37602655
[TBL] [Abstract] [Full Text] [Related]
5. Repeat stereotactic body radiotherapy for oligometastatic disease.
Willmann J; Adilovic S; Vlaskou Badra E; Christ SM; Ahmadsei M; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2023 Jul; 184():109671. PubMed ID: 37059336
[TBL] [Abstract] [Full Text] [Related]
6. lung cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell lung cancer.
Sponholz S; Koch A; Mese M; Becker S; Sebastian M; Fischer S; Trainer S; Schreiner W
Thorac Cardiovasc Surg; 2023 Dec; 71(8):656-663. PubMed ID: 36746400
[TBL] [Abstract] [Full Text] [Related]
7. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.
Rodríguez Pérez A; Felip Font E; Chicas-Sett R; Montero-Luis Á; de Paz Arias L; González-Del-Alba A; López-Campos F; López López C; Hernando Requejo O; Conde-Moreno AJ; Arranz Arija JÁ; de Castro Carpeño J
Clin Transl Oncol; 2023 Apr; 25(4):882-896. PubMed ID: 36525231
[TBL] [Abstract] [Full Text] [Related]
8. Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Conde-Moreno AJ; González-Del-Alba A; López-Campos F; López López C; Requejo OH; de Castro Carpeño J; Chicas-Sett R; de Paz Arias L; Montero-Luis Á; Pérez AR; Font EF; Arija JÁA
Clin Transl Oncol; 2023 Apr; 25(4):897-911. PubMed ID: 36525230
[TBL] [Abstract] [Full Text] [Related]
9. Stereotactic body radiation therapy for metastatic lung metastases.
Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
[TBL] [Abstract] [Full Text] [Related]
10. Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.
Stefanovic M; Calvet G; Pérez-Montero H; Esteve A; Bujalance MV; Navarro-Martín A; Fernández MDA; González FF; Borras SM; Borbalas AL; Fernandez MN; Garau MM; Calduch AL; Edo FG
Clin Transl Oncol; 2023 Jan; 25(1):199-206. PubMed ID: 36068449
[TBL] [Abstract] [Full Text] [Related]
11. Automated Computer-Aided Detection of lung Nodules in Metastatic Colorectal cancer Patients for the Identification of Pulmonary Oligometastatic Disease.
Lee JJB; Suh YJ; Oh C; Lee BM; Kim JS; Chang Y; Jeon YJ; Kim JY; Park SY; Chang JS
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):1045-1052. PubMed ID: 36028066
[TBL] [Abstract] [Full Text] [Related]
12. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract] [Full Text] [Related]
13. Recurrence patterns and impact of brain metastases in synchronous single organ oligometastatic lung cancer following local ablative treatment - A multicenter analysis.
Frost N; Roeper J; Velthaus JL; Raspe M; Olive E; Schmittel A; Schmidt B; Wasilewski D; Onken J; Lüders H; Witzenrath M; Senger C; Böhmer D; Loges S; Griesinger F; Modest DP; Grohé C
Lung Cancer; 2022 Aug; 170():165-175. PubMed ID: 35803041
[TBL] [Abstract] [Full Text] [Related]
14. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract] [Full Text] [Related]
15. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for cancer Oligometastases.
Verma V; Yegya-Raman N; Sprave T; Han G; Kantarjian HM; Welsh JW; Chang JY; Lin SH
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):977-988. PubMed ID: 35675852
[TBL] [Abstract] [Full Text] [Related]
16. Clinical value of PET/CT in identifying patients with oligometastatic/oligoprogressive disease among first-line tyrosine kinase inhibitor-treated advanced EGFR-mutant non-small cell lung cancer: Implications from survival comparisons.
Xu D; Yu F; Guo T; Zhou Y; Zhang J; Li Y; Jiang S; Mao J; Yang X; Chu L; Chu X; Wang S; Ni J; Zhu Z
Br J Radiol; 2022 Aug; 95(1136):20220035. PubMed ID: 35611637
[TBL] [Abstract] [Full Text] [Related]
17. Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy.
Andraos TY; Halmos B; Cheng H; Huntzinger C; Shirvani SM; Ohri N
Clin Lung Cancer; 2022 Jun; 23(4):291-299. PubMed ID: 35382980
[TBL] [Abstract] [Full Text] [Related]
18. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
[TBL] [Abstract] [Full Text] [Related]
19. Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell lung cancer: A Systematic Review and Meta-Analysis.
Wu Y; Verma V; Liang F; Lin Q; Zhou Z; Wang Z; Wang Y; Wang J; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):635-644. PubMed ID: 35196537
[TBL] [Abstract] [Full Text] [Related]
20. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Boch T; Frost N; Sommer L; Overbeck TR; Michaeli CT; Szuszies CJ; Rieckmann LM; Beumer N; Imbusch CD; Winter H; Thomas M; Roeper J; Janning M; Griesinger F; Wermke M; Loges S
Lung Cancer; 2022 Feb; 164():46-51. PubMed ID: 34998106
[TBL] [Abstract] [Full Text] [Related]
[Next]
